Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Chromadex Corp CS
(NQ:
CDXC
)
7.440
-0.190 (-2.49%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Chromadex Corp CS
< Previous
1
2
3
4
5
6
Next >
ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement
November 14, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
November 07, 2024
From
ChromaDex Corporation
Via
Business Wire
Insights into ChromaDex's Upcoming Earnings
October 30, 2024
Via
Benzinga
CDXC Stock Earnings: ChromaDex Misses Revenue for Q2 2024
August 07, 2024
CDXC stock results show that ChromaDex missed on revenue for the second quarter of 2024.
Via
InvestorPlace
What You Missed On Wall Street This Past Friday
November 03, 2024
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.
Via
Talk Markets
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
November 01, 2024
Via
Benzinga
Exposures
Fossil Fuels
12 Health Care Stocks Moving In Friday's Intraday Session
November 01, 2024
Via
Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
November 01, 2024
Via
Benzinga
Dow Jumps 400 Points; US Adds 12,000 Jobs In October
November 01, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
October 31, 2024
Via
Benzinga
ChromaDex Corporation Reports Third Quarter 2024 Financial Results
October 31, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
October 28, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
October 24, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in the 17th Annual LD Micro Main Event
October 23, 2024
From
ChromaDex Corporation
Via
Business Wire
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
October 15, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
September 26, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Appoints Ozan Pamir as Chief Financial Officer
September 20, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
September 10, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
September 09, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
August 23, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
August 19, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports Second Quarter 2024 Financial Results
August 07, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference
August 05, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
July 24, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
July 23, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
July 22, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
July 16, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Join Russell 2000® Index
July 01, 2024
From
ChromaDex Corporation
Via
Business Wire
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
June 24, 2024
From
ChromaDex Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
